• You will have a Ph.D or equivalent with relevant post-doctoral or industry experience.
• Demonstrable expertise in developing and running cell bioassays is essential with molecular biology, reporter gene and bioluminescent readout experience.
• Understanding assay performance criteria and the use of the right controls and standards is essential.
The successful candidate will be an independent scientist but also a team player, excellent communicator with proven writing skills. Working to the highest standards the successful candidate will work with a sense of urgency to meet the company’s ambitious goals.
PolyProX Therapeutics is a spin-out from Cambridge University, Department of Pharmacology based on exciting discoveries in the PROTACs/proteasome field. The company will discover and develop a new class of drugs for the treatment of cancer, using novel engineered proteins that are able to selectively target tumour cells and trigger natural degradation machinery within the cell. This approach promises to address cancer targets that have proved intractable using current technologies, important in major diseases such as lung, colorectal and pancreatic cancers.
PolyProX has raised seed financing of £3.4m to build and validate a drug discovery pipeline for several cancer drug targets. Based in R&D laboratories on the Babraham Research Campus we are currently recruiting a team of scientists, led by Professor Laura Itzhaki, Founder & Chief Scientific Officer.
We are seeking enthusiastic and ambitious research scientists to join our dynamic team.
To apply for this position please email your CV and a covering letter to email@example.com, quoting Ref P1903 in the e-mail header. Closing date: 28th June 2019.